Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Roth, Michael, Will, Britta, Simkin, Guillermo, Narayanagari, Swathi, Barreyro, Laura, Bartholdy, Boris, Tamari, Roni, Mitsiades, Constantine S., Verma, Amit, Steidl, Ulrich
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2012
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3398759/
https://ncbi.nlm.nih.gov/pubmed/22627766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-399667
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars